Cantor Fitzgerald Reiterates Overweight on Rocket Pharmaceuticals, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintained a $65 price target.
August 06, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Rocket Pharmaceuticals and maintained a $65 price target.
The reiteration of an Overweight rating and a maintained price target of $65 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100